{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T06:34:49Z","timestamp":1781073289310,"version":"3.54.1"},"reference-count":145,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Biochem Biotechnol"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s12010-022-04181-3","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T06:02:45Z","timestamp":1665554565000},"page":"1541-1573","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["SARS-CoV-2 Vaccines: Types, Working Principle, and Its Impact on Thrombosis and Gastrointestinal Disorders"],"prefix":"10.1007","volume":"195","author":[{"given":"Shubhra","family":"Khare","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Niharika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajey","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imtiyaz","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6176-255X","authenticated-orcid":false,"given":"Narsingh Bahadur","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhash","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,12]]},"reference":[{"key":"4181_CR1","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S1473-3099(20)30120-1","volume":"20","author":"E Dong","year":"2020","unstructured":"Dong, E., Du, H., & Gardner, L. (2020). An interactive web-based dashboard to track COVID-19 in real time. The Lancet Infectious Diseases, 20, 533\u2013534.","journal-title":"The Lancet Infectious Diseases"},{"key":"4181_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102743","author":"E Kim","year":"2020","unstructured":"Kim, E., et al. (2020). Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development. EBio Med. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102743","journal-title":"EBio Med"},{"issue":"5","key":"4181_CR3","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","volume":"8","author":"X Yang","year":"2020","unstructured":"Yang, X., Yu, Y., Xu, J., Shu, H., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., Yu, T., & Wang, Y. (2020). Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. The Lancet Respiratory Med, 8(5), 475\u2013481.","journal-title":"The Lancet Respiratory Med"},{"issue":"3","key":"4181_CR4","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41579-020-00462-y","volume":"19","author":"S Su","year":"2021","unstructured":"Su, S., Du, L., & Jiang, S. (2021). Learning from the past: development of safe and effective COVID-19 vaccines. Nature Reviews Microbiology, 19(3), 211\u2013219. https:\/\/doi.org\/10.1038\/s41579-020-00462-y","journal-title":"Nature Reviews Microbiology"},{"issue":"5","key":"4181_CR5","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/d41573-020-00073-5","volume":"19","author":"TT Le","year":"2020","unstructured":"Le, T. T., Andreadakis, Z., Kumar, A., Rom\u00e1n, R. G., Tollefsen, S., Saville, M., & Mayhew, S. (2020). The COVID-19 vaccine development landscape. Nature Reviews. Drug Discovery, 19(5), 305\u2013306.","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"10","key":"4181_CR6","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/d41573-020-00151-8","volume":"19","author":"TT Le","year":"2020","unstructured":"Le, T. T., Cramer, J. P., Chen, R., & Mayhew, S. (2020). Evolution of the COVID-19 vaccine development landscape. Nature Reviews Drug Discovery, 19(10), 667\u20138. https:\/\/doi.org\/10.1038\/d41573-020-00151-8","journal-title":"Nature Reviews Drug Discovery"},{"key":"4181_CR7","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Marc, G. P., Moreira, E. D., Zerbini, C., & Bailey, R. (2020). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. The New England Journal of Medicine, 383, 2603\u20132615. https:\/\/doi.org\/10.1056\/NEJMoa2034577","journal-title":"The New England Journal of Medicine"},{"issue":"13","key":"4181_CR8","doi-asserted-by":"publisher","first-page":"495","DOI":"10.15585\/mmwr.mm7013e3","volume":"70","author":"MG Thompson","year":"2021","unstructured":"Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H. L., Yoon, S. K., Meece, J., Olsho, L. E., Caban-Martinez, A. J., Fowlkes, A., Lutrick, K., & Kuntz, J. L. (2021). Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers\u2014eight US locations, December 2020\u2013March 2021. Morbidity and Mortality Weekly Report., 70(13), 495.","journal-title":"Morbidity and Mortality Weekly Report."},{"key":"4181_CR9","doi-asserted-by":"crossref","unstructured":"Sapkal, G.N., Yadav, P.D., Ella, R., Deshpande, G.R., Sahay, R.R., Gupta, N., Vadrevu, K.M., Abraham, P., Panda, S. &Bhargava, B., (2021). Inactivated COVID-19 vaccine BBV152\/COVAXIN effectively neutralizes recently emerged B. 1.1. 7 variant of SARS-CoV-2. Journal of Travel Medicine 28(4).","DOI":"10.1093\/jtm\/taab051"},{"key":"4181_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101020","volume":"38","author":"T Momin","year":"2021","unstructured":"Momin, T., Kansagra, K., Patel, H., Sharma, S., Sharma, B., Patel, J., Mittal, R., Sanmukhani, J., Maithal, K., Dey, A., & Chandra, H. (2021). Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I\/II clinical study by intradermal route in healthy subjects in India. EClinicalMedicine, 38, 101020.","journal-title":"EClinicalMedicine"},{"issue":"1","key":"4181_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","volume":"21","author":"S Xia","year":"2021","unstructured":"Xia, S., Zhang, Y., Wang, Y., Wang, H., Yang, Y., Gao, G. F., Tan, W., Wu, G., Xu, M., Lou, Z., & Huang, W. (2021). Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: A randomised, double-blind, placebo-controlled, phase 1\/2 trial. The Lancet Infectious Diseases, 21(1), 39\u201351.","journal-title":"The Lancet Infectious Diseases"},{"key":"4181_CR12","unstructured":"CureVac Announces Positive Results in Low Dose \u2013 1 \u03bcg \u2013 Rabies Vaccine Clinical Phase 1 Study. (2020). https:\/\/www.curevac.com\/en\/2020\/01\/07\/curevac-announces-positive-results-in-low-dose-1-%C2%B5g-rabies-vaccine-clinicalphase-1-study\/"},{"key":"4181_CR13","doi-asserted-by":"crossref","unstructured":"Al Kaabi, N., Zhang, Y., Xia, S., Yang, Y., Al Qahtani, M.M., et al., (2021). Effect of 2 Inactivated SARS-CoV-2 Vaccines on symptomatic COVID-19 infection in adults: A randomized clinical trial.\u00a0JAMA.","DOI":"10.1001\/jama.2021.8565"},{"key":"4181_CR14","doi-asserted-by":"crossref","unstructured":"Huang, B., Dai, L., Wang, H., Hu, Z., Yang, X., Tan, W. and Gao, G.F., (2021). Serum sample neutralisation of BBIBP-CorV and ZF2001 vaccines to SARS-CoV-2 501Y. V2.\u00a0The Lancet Microbe.","DOI":"10.1016\/S2666-5247(21)00082-3"},{"key":"4181_CR15","unstructured":"Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial. https:\/\/ir.novavax.com\/news-releases\/newsrelease-details\/novavax-covid-19-vaccine-demonstrates-893-efficacyuk-phase-3\u00a0(accessed March 10, 2021)."},{"key":"4181_CR16","doi-asserted-by":"crossref","unstructured":"Yang, S., Li, Y., Dai, L., Wang, J., He, P., Li, C., Fang, X., Wang, C., Zhao, X., Huang, E. and Wu, C., (2021). Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: Two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. The Lancet Infectious Diseases.","DOI":"10.1016\/S1473-3099(21)00127-4"},{"issue":"10269","key":"4181_CR17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., et al. (2021). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet, 397(10269), 99\u2013111.","journal-title":"Lancet"},{"key":"4181_CR18","doi-asserted-by":"publisher","unstructured":"Edward, H., Livingston, M.D.; Preeti, N., Malani, M.D., MSJ; C. Buddy Creech, M.D., MPH March 1, 2021. doi:https:\/\/doi.org\/10.1001\/jama.2021.2927 Deputy Editor, JAMA (Livingston); Associate Editor, JAMA (Malani).","DOI":"10.1001\/jama.2021.2927"},{"key":"4181_CR19","doi-asserted-by":"crossref","unstructured":"Logunov, D.Y., Dolzhikova , IV &Shcheblyakov, D.V., et al. (2021). Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia. Lancet.","DOI":"10.1016\/S0140-6736(21)00234-8"},{"key":"4181_CR20","unstructured":"NMPA Accepts the Application for Conditional Marketing Authorization of CanSinoBIO\u2019s COVID-19 Vaccine ConvideciaTM. http:\/\/www.cansinotech.com\/html\/1\/\/\/179\/180\/651.html (accessed March 12, 2021)."},{"key":"4181_CR21","doi-asserted-by":"publisher","unstructured":"Malik, J. A., Mulla, A. H., Farooqi, T., Pottoo, F. H., Anwar, S. & Rengasamy, K. R. (2021). Targets and strategies for vaccine development against SARS-CoV-2. Biomedicine & Pharmacotherapy 137, 111254. https:\/\/doi.org\/10.1016\/j.biopha.2021.111254","DOI":"10.1016\/j.biopha.2021.111254"},{"issue":"2","key":"4181_CR22","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.vaccine.2020.11.054","volume":"39","author":"T Ura","year":"2021","unstructured":"Ura, T., Yamashita, A., Mizuki, N., Okuda, K., & Shimada, M. (2021). New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates. Vaccine, 39(2), 197\u2013201. https:\/\/doi.org\/10.1016\/j.vaccine.2020.11.054","journal-title":"Vaccine"},{"issue":"3","key":"4181_CR23","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.cell.2020.06.008","volume":"182","author":"H Wang","year":"2020","unstructured":"Wang, H., Zhang, Y., Huang, B., Deng, W., Quan, Y., Wang, W., Xu, W., Zhao, Y., Li, N., Zhang, J., & Liang, H. (2020). Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell, 182(3), 713\u2013721. https:\/\/doi.org\/10.1016\/j.cell.2020.06.008","journal-title":"Cell"},{"key":"4181_CR24","unstructured":"World Health Organization MODULE 2- Types of vaccine and adverse reactions WHO. 41\u201342 (2018). https:\/\/www.who.int\/vaccine_safety\/initiative\/tech_support\/Part-2.pdf."},{"issue":"8","key":"4181_CR25","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/s41563-020-0746-0","volume":"19","author":"D van Riel","year":"2020","unstructured":"van Riel, D., & de Wit, E. (2020). Next-generation vaccine platforms for COVID-19. Nat Mat, 19(8), 810\u2013812.","journal-title":"Nat Mat"},{"key":"4181_CR26","doi-asserted-by":"crossref","unstructured":"Dong, Y., Dai, T., Wei, Y., Zhang, L., Zheng, M., et al., (2020). A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduction and Targeted Therapy, 5.","DOI":"10.1038\/s41392-020-00352-y"},{"key":"4181_CR27","unstructured":"Serum Institute of India Initiates Manufacturing of Codagenix\u2019s Intranasal Live-Attenuated COVID-19 Vaccine Candidate. https:\/\/www.prnewswire.com\/newsreleases\/serum-institute-of-india-initiatmanufacturing-of-codagenixs-intranasal-live-attenuated-covid-19-vaccine-candidate-301135221.html (accessed December 11, 2020)."},{"issue":"1","key":"4181_CR28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.anai.2020.01.025","volume":"125","author":"PL Stern","year":"2020","unstructured":"Stern, P. L. (2020). Key steps in vaccine development. Annals of Allergy, Asthma & Immunology, 125(1), 17\u201327. https:\/\/doi.org\/10.1016\/j.anai.2020.01.025","journal-title":"Annals of Allergy, Asthma & Immunology"},{"key":"4181_CR29","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3390\/vaccines3020373","volume":"3","author":"S Sridhar","year":"2015","unstructured":"Sridhar, S., Brokstad, K. A., & Cox, R. J. (2015). Influenza vaccination strategies: Comparing inactivated and live attenuated influenza vaccines. Vaccines, 3, 373\u2013389. https:\/\/doi.org\/10.3390\/vaccines3020373","journal-title":"Vaccines"},{"key":"4181_CR30","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41577-020-00434-6","volume":"20","author":"M Jeyanathan","year":"2020","unstructured":"Jeyanathan, M., Afkhami, S., Smaill, F., Miller, M. S., Lichty, B. D., & Xing, Z. (2020). Immunological considerations for COVID-19 vaccine strategies. Nature Reviews Immunology, 20, 615\u2013632.","journal-title":"Nature Reviews Immunology"},{"issue":"6499","key":"4181_CR31","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1126\/science.abc1932","volume":"369","author":"Q Gao","year":"2020","unstructured":"Gao, Q., Bao, L., Mao, H., Wang, L., Xu, K., Yang, M., Li, Y., Zhu, L., Wang, N., Lv, Z., & Gao, H. (2020). Development of an inactivated vaccine candidate for SARS-CoV-2. Science, 369(6499), 77\u201381.","journal-title":"Science"},{"key":"4181_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.579250","volume":"11","author":"KL Flanagan","year":"2020","unstructured":"Flanagan, K. L., Best, E., Crawford, N. W., et al. (2020). Progress and pitfalls in the quest for effective SARS-CoV-2 (COVID-19) vaccines. Frontiers in Immunology, 11, 579250.","journal-title":"Frontiers in Immunology"},{"key":"4181_CR33","unstructured":"World Health Organization. 2020. Draft landscape of COVID 19 candidate Vaccines. https:\/\/www.Who.Int\/Who-Documents-Detail\/Draft-Landscape-Of-Covid-19-Candidate-Vaccines [WWW Document] accessed 10.30.20."},{"key":"4181_CR34","doi-asserted-by":"publisher","first-page":"244","DOI":"10.4103\/ijmr.IJMR_1029_20","volume":"151","author":"P Sarkale","year":"2020","unstructured":"Sarkale, P., Patil, S., Yadav, P., et al. (2020). First isolation of SARS-CoV-2 from clinical samples in India. Indian Journal of Medical Research, 151, 244\u2013250.","journal-title":"Indian Journal of Medical Research"},{"key":"4181_CR35","doi-asserted-by":"crossref","unstructured":"Ella, R., Reddy, S., Jogdand, H., Sarangi, V., et al., (2021). Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: Interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial.\u00a0The Lancet Infectious Diseases.","DOI":"10.1016\/S1473-3099(21)00070-0"},{"key":"4181_CR36","doi-asserted-by":"crossref","unstructured":"Baraniuk, C., (2021). What do we know about China\u2019s covid-19 vaccines?.\u00a0bmj,\u00a0373.","DOI":"10.1136\/bmj.n912"},{"issue":"4","key":"4181_CR37","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.idnow.2021.02.007","volume":"51","author":"M Lefebvre","year":"2021","unstructured":"Lefebvre, M., Vignier, N., Pitard, B., Botelho-Nevers, E., Cohen, R., & Epaulard, O. (2021). Covid-19 vaccines: Frequently asked questions and updated answers. Infectious Diseases Now, 51(4), 319\u2013333.","journal-title":"Infectious Diseases Now"},{"issue":"10","key":"4181_CR38","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1001\/jama.2020.15543","volume":"324","author":"S Xia","year":"2020","unstructured":"Xia, S., Duan, K., Zhang, Y., Zhao, D., Zhang, H., Xie, Z., Li, X., Peng, C., Zhang, Y., Zhang, W., & Yang, Y. (2020). Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. Jama, 324(10), 951\u2013960. https:\/\/doi.org\/10.1001\/jama.2020.15543","journal-title":"Jama"},{"key":"4181_CR39","unstructured":"Parekh, N., (2020).\u00a0\u201cCoronaVac: A COVID-19 Vaccine Made From Inactivated SARS-CoV-2 Virus\u201d. Retrieved\u00a025 July2020"},{"key":"4181_CR40","doi-asserted-by":"publisher","unstructured":"Zhang Y.-J., G. Zeng, H.-X. Pan, C.-G. Li, B. Kan, Y.-L. Hu, H.-Y. Mao, Q.-Q. Xin, K. Chu, W.-X. Han, Z. Chen, R. Tang, W.-D. Yin, X. Chen, X.-J. Gong, C. Qin, Y.-S. Hu, X.-Y. Liu,G.-L. Cui, C.-B. Jiang, H.-M. Zhang, J.-X. Li, M.-N. Yang, X.-J. Lian, Y. Song, J.-X. Lu, X.-X. Wang, M. Xu, Q. Gao, F.-C. Zhu. (2020). Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults aged 18\u201359 years: Report of the randomized, double-blind, and placebo-controlled phase 2 clinical trial. medRxiv 2020.07.31.20161216 [Preprint]. 10 August 2020. https:\/\/doi.org\/10.1101\/2020.07.31.20161216","DOI":"10.1101\/2020.07.31.20161216"},{"key":"4181_CR41","unstructured":"AGENCIES, DAILY SABAH WITH (2020).\u00a0\u201cTurkey set to receive \u2018effective\u2019 COVID-19 vaccine amid calls for inoculation\u201d.\u00a0Daily Sabah. Retrieved\u00a012 February\u00a02021."},{"key":"4181_CR42","unstructured":"\u201cCoronaVac: Doses will come from China on nine flights and can\u2026\u201d\u00a0AlKhaleej Today\u00a0(in Arabic). 1 November 2020.\u00a0Archivedfrom the original on 16 December 2020. Retrieved\u00a01 November2020."},{"key":"4181_CR43","unstructured":"Staff. (2020). \u201cChina\u2019s Sinovac coronavirus vaccine candidate appears safe, slightly weaker in elderly\u201d. Reuters. Archived from the original on 7 October 2020."},{"key":"4181_CR44","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1021\/acscentsci.1c00120","volume":"7","author":"Li","year":"2021","unstructured":"Li, et al. (2021). ACS Central Science, 7, 512\u2013533.","journal-title":"ACS Central Science"},{"key":"4181_CR45","doi-asserted-by":"publisher","first-page":"11157","DOI":"10.1073\/pnas.1708727114","volume":"114","author":"AC Walls","year":"2017","unstructured":"Walls, A. C., et al. (2017). Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion. Proceedings of the National Academy of Sciences of the United States of America, 114, 11157\u201311162.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"4181_CR46","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1146\/annurev-virology-110615-042301","volume":"3","author":"F Li","year":"2016","unstructured":"Li, F., et al. (2016). Structure, function, and evolution of coronavirus spike proteins. Annual Review of Virology, 3, 237\u2013261.","journal-title":"Annual Review of Virology"},{"key":"4181_CR47","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41467-020-15562-9","volume":"1620","author":"X Ou","year":"2020","unstructured":"Ou, X., Liu, Y., Lei, X., et al. (2020). Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nature Communications, 1620, 11. https:\/\/doi.org\/10.1038\/s41467-020-15562-9","journal-title":"Nature Communications"},{"key":"4181_CR48","doi-asserted-by":"crossref","unstructured":"Graham, B.S., (2020). Rapid COVID-19 vaccine development. Science (May 29), 945\u2013946.","DOI":"10.1126\/science.abb8923"},{"key":"4181_CR49","doi-asserted-by":"publisher","unstructured":"Coutard, B., et al. (2020). The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Research, 176, 04742. https:\/\/doi.org\/10.1016\/j.antiviral.2020.104742","DOI":"10.1016\/j.antiviral.2020.104742"},{"key":"4181_CR50","first-page":"E7348","volume":"114","author":"J Pallesen","year":"2017","unstructured":"Pallesen, J., et al. (2017). Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proceedings of the National Academy of Sciences of the United States of America, 114, E7348\u2013E7357.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"4181_CR51","doi-asserted-by":"publisher","first-page":"15214","DOI":"10.1073\/pnas.1407087111","volume":"111","author":"JK Millet","year":"2014","unstructured":"Millet, J. K., & Whittaker, G. R. (2014). Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein. Proceedings of the National academy of Sciences of the United States of America, 111, 15214\u201315219.","journal-title":"Proceedings of the National academy of Sciences of the United States of America"},{"key":"4181_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.00298","author":"W Ning","year":"2020","unstructured":"Ning, W., Jian, S., Shibo, J., & Lanying, Du. (2020). Subunit vaccines against emerging pathogenic human coronaviruses. Frontiers in Microbiology. https:\/\/doi.org\/10.3389\/fmicb.2020.00298","journal-title":"Frontiers in Microbiology"},{"issue":"1","key":"4181_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-018-06151-y","volume":"9","author":"Y Cao","year":"2018","unstructured":"Cao, Y., Zhu, X., Hossen, M. N., Kakar, P., Zhao, Y., & Chen, X. (2018). Augmentation of vaccine-induced humoral and cellular immunity by a physical radiofrequency adjuvant. Nature Communication, 9(1), 1\u201313. https:\/\/doi.org\/10.1038\/s41467-018-06151-y","journal-title":"Nature Communication"},{"key":"4181_CR54","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","volume":"586","author":"F Krammer","year":"2020","unstructured":"Krammer, F. (2020). SARS-CoV-2 vaccines in development. Nature, 586, 516\u2013527.","journal-title":"Nature"},{"issue":"6","key":"4181_CR55","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.3390\/jcm9061885","volume":"9","author":"D Wu","year":"2020","unstructured":"Wu, D., Koganti, R., Lambe, U. P., Yadavalli, T., Nandi, S. S., & Shukla, D. (2020). Vaccines and therapies in development for SARS-CoV-2 infections. Journal of Clinical Medicine, 9(6), 1885. https:\/\/doi.org\/10.3390\/jcm9061885","journal-title":"Journal of Clinical Medicine"},{"key":"4181_CR56","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/imr.12863","volume":"296","author":"MO Mohsen","year":"2020","unstructured":"Mohsen, M. O., Augusto, G., & Bachmann, M. F. (2020). The 3Ds in virus-like particle based-vaccines: \u2033Design, delivery and dynamics. Immunological Reviews, 296, 155\u2013168.","journal-title":"Immunological Reviews"},{"key":"4181_CR57","doi-asserted-by":"publisher","unstructured":"Arora, K., Rastogi, R., et al., (2020). Multi-Antigenic Virus-like Particle of SARS CoV-2 produced in Saccharomyces cerevisiae as a vaccine candidate. Gurugram :s.n. bioRxiv (May 19). https:\/\/doi.org\/10.1101\/2020.05.18.099234","DOI":"10.1101\/2020.05.18.099234"},{"key":"4181_CR58","doi-asserted-by":"publisher","unstructured":"Coleman, C. M., Liu, Y. V., & Mu, H. (2020). Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine, 3169\u20133174,. https:\/\/doi.org\/10.1016\/j.vaccine.2014.04.016","DOI":"10.1016\/j.vaccine.2014.04.016"},{"key":"4181_CR59","doi-asserted-by":"crossref","unstructured":"Tu, Y.-F., Chien, C.-S., Yarmishyn, A.A., Lin, Y.-Y., Luo, Y.-H., Lin, Y.-Y., Lai, W.-Y., Yang, D.-M., Chou, S.-J., Yang, Y.-P., Wang, M.-L. & Chiou, S.-H., (2020). A review of SARS-CoV-2 and the ongoing clinical trials. International Journal of Molecular Sciences, 2657.","DOI":"10.3390\/ijms21072657"},{"key":"4181_CR60","unstructured":"Novavax covid 19 vaccine trial, (2020). Clinical Trials Arena [Online].  altrialsarena.com\/news\/novavax-covid-19-vaccine-trial\/."},{"key":"4181_CR61","doi-asserted-by":"crossref","unstructured":"An, Y., Li, S., Jin, X., Han, J.B., Xu, K., Xu, S., Han, Y., Liu, C., Zheng, T., Liu, M. and Yang, M., (2021). A tandem-repeat dimeric RBD protein-based COVID-19 vaccine ZF2001 protects mice and nonhuman primates. bioRxiv.","DOI":"10.1101\/2021.03.11.434928"},{"key":"4181_CR62","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.gendis.2017.04.001","volume":"4","author":"CS Lee","year":"2017","unstructured":"Lee, C. S., Bishop, E. S., Zhang, R., Yu, X., Farina, E. M., Yan, S., Zhao, C., et al. (2017). Adenovirus-mediated gene delivery: Potential applications for gene and cell-based therapies in the new era of personalized medicine. Genes & Diseases, 4, 43\u201363.","journal-title":"Genes & Diseases"},{"issue":"4","key":"4181_CR63","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.cell.2020.04.011","volume":"181","author":"D Kim","year":"2020","unstructured":"Kim, D., Lee, J. Y., Yang, J. S., Kim, J. W., Kim, V. N., & Chang, H. (2020). The architecture of SARS-CoV-2 transcriptome. Cell, 181(4), 914\u2013921.","journal-title":"Cell"},{"key":"4181_CR64","doi-asserted-by":"publisher","first-page":"1 e6","DOI":"10.4110\/in.2021.21.e6","volume":"21","author":"J Chang","year":"2021","unstructured":"Chang, J. (2021). Adenovirus vectors: Excellent tools for vaccine development. Immune Network, 21, 1 e6. https:\/\/doi.org\/10.4110\/in.2021.21.e6","journal-title":"Immune Network"},{"issue":"2","key":"4181_CR65","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3390\/pharmaceutics13020140","volume":"13","author":"A Bouazzaoui","year":"2021","unstructured":"Bouazzaoui, A., Abdellatif, A. A., Al-Allaf, F. A., Bogari, N. M., Al-Dehlawi, S., & Qari, S. H. (2021). Strategies for vaccination: conventional vaccine approaches versus new-generation strategies in combination with adjuvants. Pharmaceutics, 13(2), 140. https:\/\/doi.org\/10.3390\/pharmaceutics13020140","journal-title":"Pharmaceutics"},{"key":"4181_CR66","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1038\/mt.2009.130","volume":"28","author":"EJ Kremer","year":"2020","unstructured":"Kremer, E. J. (2020). Pros and Cons of Adenovirus-Based SARS-CoV-2 Vaccines. Molecular Therapy, 28, 2303\u20132304. https:\/\/doi.org\/10.1038\/mt.2009.130","journal-title":"Molecular Therapy"},{"key":"4181_CR67","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1089\/hum.2013.235","volume":"25","author":"D Majhen","year":"2014","unstructured":"Majhen, D., Calderon, H., Chandra, N., Fajardo, C. A., Rajan, A., Alemany, R., & Custers, J. (2014). Adenovirus-based vaccines for fighting infectious diseases and cancer: Progress in the field. Human Gene Therapy, 25, 301\u2013317.","journal-title":"Human Gene Therapy"},{"issue":"8","key":"4181_CR68","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/mt.2009.130","volume":"17","author":"MO Lasaro","year":"2009","unstructured":"Lasaro, M. O., & Ertl, H. C. (2009). New insights on adenovirus as vaccine vectors. Molecular Therapy, 17(8), 1333\u20131339. https:\/\/doi.org\/10.1038\/mt.2009.130","journal-title":"Molecular Therapy"},{"key":"4181_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2020.198114","volume":"288","author":"SP Kaur","year":"2020","unstructured":"Kaur, S. P., & Gupta, V. (2020). COVID-19 vaccine: A comprehensive status report. Virus Research, 288, 198114.","journal-title":"Virus Research"},{"key":"4181_CR70","doi-asserted-by":"publisher","unstructured":"Wise, J. (2021). Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots. BMJ, 372. https:\/\/doi.org\/10.1136\/bmj.n699","DOI":"10.1136\/bmj.n699"},{"key":"4181_CR71","unstructured":"WHO Statement on AstraZeneca COVID-19 vaccine safety signals. Available online: https:\/\/www.who.int\/news\/item\/17-03-2021-who-statement-on-astrazeneca-covid-19-vaccine-safety-signals (accessed on 23 March 2021)."},{"key":"4181_CR72","doi-asserted-by":"crossref","unstructured":"Sadoff, J., Le Gars, M., Shukarev, G., Heerwegh, D., Truyers, C., De Groot, A.M., Stoop, J., Tete, S., Van Damme, W., Leroux-Roels, I., et al. (2021). Interim results of a phase 1\u20132a Trial of Ad26.COV2.S Covid-19 vaccine. The New England Journal of Medicine, 2034201.","DOI":"10.1056\/NEJMoa2034201"},{"key":"4181_CR73","unstructured":"FDA Briefing Document, 2021. Janssen Ad26.COV2.S vaccine for the prevention of COVID-19. In: Vaccines and related biological products advisory committee meeting; 2021. February 26, https:\/\/www.fda.gov\/media\/146217\/download. Accessed on April 8, 2021."},{"key":"4181_CR74","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.1016\/j.vaccine.2011.05.025","volume":"29","author":"DH Barouch","year":"2011","unstructured":"Barouch, D. H., Kik, S. V., Weverling, G. J., et al. (2011). International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine, 29, 5203\u20135209.","journal-title":"Vaccine"},{"key":"4181_CR75","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.coi.2009.05.016","volume":"21","author":"S Lu","year":"2009","unstructured":"Lu, S. (2009). Heterologous prime-boost vaccination. Current Opinion in Immunology, 21, 346\u2013351.","journal-title":"Current Opinion in Immunology"},{"issue":"10240","key":"4181_CR76","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","volume":"395","author":"FC Zhu","year":"2020","unstructured":"Zhu, F. C., Li, Y. H., Guan, X. H., Hou, L. H., Wang, W. J., Li, J. X., Wu, S. P., Wang, B. S., Wang, Z., Wang, L., & Jia, S. Y. (2020). Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a doseescalation, open-label, non-randomised, first-in-human trial. The Lancet, 395(10240), 1845\u20131854. https:\/\/doi.org\/10.1016\/S0140-6736(20)31208-3","journal-title":"The Lancet"},{"key":"4181_CR77","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3390\/vaccines2030624","volume":"2","author":"T Ura","year":"2014","unstructured":"Ura, T., Okuda, K., & Shimada, M. (2014). Developments in Viral Vector-Based Vaccines. Vaccines, 2, 624\u2013641.","journal-title":"Vaccines"},{"key":"4181_CR78","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.chom.2020.07.018","volume":"28","author":"JB Case","year":"2020","unstructured":"Case, J. B., et al. (2020). Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis in mice. Cell Host & Microbe, 28, 465-474.e4.","journal-title":"Cell Host & Microbe"},{"key":"4181_CR79","doi-asserted-by":"publisher","first-page":"10862","DOI":"10.1128\/JVI.00928-12","volume":"86","author":"H Li","year":"2021","unstructured":"Li, H., Rhee, G., Masek-Hammerman, K., Teigler, J. E., Abbink, P., & Barouch, D. H. (2021). Adenovirus serotype 26 utilizes CD46 as a primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys. Journal of Virology, 86, 10862\u201310865.","journal-title":"Journal of Virology"},{"key":"4181_CR80","doi-asserted-by":"publisher","unstructured":"Rauch, S., Gooch, K., Hall, Y., Salguero, F. J., Dennis, M. J., Gleeson, F. V., Harris, D., Ho, C., Humphries, H. E., Longet, S., & Ngabo, D. (2020). mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 challenge infection. Biorxiv. https:\/\/doi.org\/10.1101\/2020.12.23.424138","DOI":"10.1101\/2020.12.23.424138"},{"issue":"1","key":"4181_CR81","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/abbs\/36.1.37","volume":"36","author":"P Zhao","year":"2004","unstructured":"Zhao, P., Ke, J. S., Qin, Z. L., Ren, H., Zhao, L. J., Yu, J. G., Gao, J., Zhu, S. Y., & Qi, Z. T. (2004). DNA vaccine of SARSCovS gene induces antibody response in mice. Acta biochimica et biophysica Sinica, 36(1), 37\u201341. https:\/\/doi.org\/10.1093\/abbs\/36.1.37","journal-title":"Acta biochimica et biophysica Sinica"},{"key":"4181_CR82","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/978-3-540-92165-3","volume":"333","author":"JHJJ Kim","year":"2009","unstructured":"Kim, J. H. J. J. (2009). DNA vaccines against Influenza viruses. Vaccines for pandemic influenza, 333, 197\u2013210. https:\/\/doi.org\/10.1007\/978-3-540-92165-3","journal-title":"Vaccines for pandemic influenza"},{"key":"4181_CR83","unstructured":"WHO. Draft landscape of COVID-19 candidate vaccines. Jan 15, 2021. https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19- candidate-vaccines (accessed Jan 15, 2021)."},{"key":"4181_CR84","doi-asserted-by":"crossref","unstructured":"Yadav, P., Kumar, S., Agarwal, K., Jain, M., Patil, D., Maithal, K., Mathapati, B., Giri, S., Mohandas, S., Shete, A. and Sapkal, G., (2021). Assessment of immunogenicity and protective efficacy of ZyCoV-D DNA vaccine candidates in Rhesus macaques against SARS-CoV-2 infection. BioRxiv.","DOI":"10.1101\/2021.02.02.429480"},{"key":"4181_CR85","doi-asserted-by":"crossref","unstructured":"Dey, A., Rajanathan, C., Chandra, H., Pericherla, H.P., Kumar, S., Choonia, H.S., Bajpai, M., Singh, A.K., Sinha, A., Saini, G. and Dalal, P., (2021). Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in Animal Models. bioRxiv.","DOI":"10.1101\/2021.01.26.428240"},{"issue":"2","key":"4181_CR86","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41591-021-01446-y","volume":"3","author":"JP Sahoo","year":"2021","unstructured":"Sahoo, J. P., Nath, S., Ghosh, L., & Samal, K. C. (2021). Concepts of immunity and recent immunization programme against COVID-19 in India. Biotics Research Today, 3(2), 103\u2013106. https:\/\/doi.org\/10.1038\/s41591-021-01446-y","journal-title":"Biotics Research Today"},{"issue":"2019","key":"4181_CR87","first-page":"1","volume":"15","author":"KJ Hassett","year":"2015","unstructured":"Hassett, K. J., Benenato, K. E., Jacquinet, E., et al. (2015). Optimization of lipid nanoparticles forintramuscular administration of mRNA vaccines Mol. Ther. Nucleic Acids, 15(2019), 1\u201311.","journal-title":"Ther. Nucleic Acids"},{"key":"4181_CR88","doi-asserted-by":"publisher","first-page":"24075","DOI":"10.1073\/pnas.1908052116","volume":"116","author":"DM Mauger","year":"2019","unstructured":"Mauger, D. M., Cabral, B. J., Presnyak, V., Su, S. V., et al. (2019). mRNA structure regulates protein expression through changes in functional half-life. Proceedings of the National Academy of Sciences of the United States of America, 116, 24075.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"4181_CR89","doi-asserted-by":"crossref","unstructured":"Lutz, J., Lazzaro, S., Habbeddine, M., et al., (2017). Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines. npjVaccines 2.","DOI":"10.1038\/s41541-017-0032-6"},{"key":"4181_CR90","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.jconrel.2021.03.043","volume":"333","author":"R Verbeke","year":"2021","unstructured":"Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2021). The dawn of mRNA vaccines: The COVID-19 case. Journal of Controlled Release, 333, 511\u2013520.","journal-title":"Journal of Controlled Release"},{"key":"4181_CR91","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1084\/jem.20171450","volume":"215","author":"N Pardi","year":"2018","unstructured":"Pardi, N., Hogan, M. J., Naradikian, M. S., Parkhouse, K., Cain, D. W., Jones, L., Moody, M. A., Verkerke, H. P., Myles, A., Willis, E., et al. (2018). Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. Journal of Experimental Medicine, 215, 1571\u20131588.","journal-title":"Journal of Experimental Medicine"},{"key":"4181_CR92","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.ymthe.2018.12.011","volume":"27","author":"AG Orlandini von Niessen","year":"2019","unstructured":"Orlandini von Niessen, A. G., Poleganov, M. A., Rechner, C., Plaschke, A., Kranz, L. M., Fesser, S., Diken, M., et al. (2019). Improving mRNA-based therapeutic gene delivery by expression-augmenting 3\u2019 UTRs identified by cellular library screening. Molecular Therapy, 27, 824\u2013836.","journal-title":"Molecular Therapy"},{"issue":"1","key":"4181_CR93","first-page":"1","volume":"6","author":"S Rauch","year":"2020","unstructured":"Rauch, S., Roth, N., Schwendt, K., Fotin-Mleczek, M., Mueller, S. O., & Petsch, B. (2020). mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents. NPJ Vaccines., 6(1), 1\u20139.","journal-title":"NPJ Vaccines."},{"key":"4181_CR94","unstructured":"European Medicines Agency, 2020. EMA recommends first COVID-19 vaccine for authorisation in the EU.https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-first-covid-19-vaccine-authorisation-eu"},{"key":"4181_CR95","doi-asserted-by":"crossref","unstructured":"Burki T., 2021. Equitable distribution of COVID-19 vaccines. Lancet. 21(1), P33\u20134. Swissmedic. Comirnaty R: Fachinformation. 2020. http:\/\/www.swiss medic info.ch. Accessed 11 Feb 2021.","DOI":"10.1016\/S1473-3099(20)30949-X"},{"issue":"7830","key":"4181_CR96","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","volume":"586","author":"MJ Mulligan","year":"2020","unstructured":"Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., et al. (2020). Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature, 586(7830), 589\u2013593. https:\/\/doi.org\/10.1038\/s41586-020-2639-4","journal-title":"Nature"},{"key":"4181_CR97","unstructured":"Herper, M., (2020). \"Covid-19 vaccine from Pfizer and BioNTech is strongly effective, early data from large trial indicate\".\u00a0STAT.\u00a0Archived\u00a0from the original on 9 November 2020."},{"issue":"16","key":"4181_CR98","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","volume":"383","author":"KS Corbett","year":"2020","unstructured":"Corbett, K. S., Flynn, B., Foulds, K. E., Francica, J. R., et al. (2020). Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. The New England Journal of Medicine, 383(16), 1544\u20131555.","journal-title":"The New England Journal of Medicine"},{"key":"4181_CR99","doi-asserted-by":"publisher","unstructured":"Chemaitelly, H., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., Tang, P., Hasan, M. R., Malek, J. A., Coyle, P., Ayoub, H. H., Al Kanaani, Z., & Al Kuwari, E. (2021). mRNA-1273 COVID-19 vaccine effectiveness against the B. 1.1. 7 and B. 1.351 variants and severe COVID-19 disease in Qatar. Nature Medicine, 27(9), 1614\u20131621. https:\/\/doi.org\/10.1038\/s41591-021-01446-y","DOI":"10.1038\/s41591-021-01446-y"},{"issue":"10275","key":"4181_CR100","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/S0140-6736(21)00191-4","volume":"397","author":"I Jones","year":"2021","unstructured":"Jones, I., & Roy, P. (2021). Sputnik V COVID-19 vaccine candidates appears safe and effective. The Lancet., 397(10275), 642\u2013643.","journal-title":"The Lancet."},{"key":"4181_CR101","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3390\/vaccines8040574","volume":"8","author":"EE Sayedahmed","year":"2020","unstructured":"Sayedahmed, E. E., Elkashif, A., Alhashimi, M., Sambhara, S., & Mittal, S. K. (2020). Adenoviral vector-based vaccine platforms for developing the next generation of influenza vaccines. Vaccines., 8, 574.","journal-title":"Vaccines."},{"key":"4181_CR102","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/j.celrep.2015.10.034","volume":"13","author":"B Bolinger","year":"2015","unstructured":"Bolinger, B., Sims, S., Swadling, L., O\u2019Hara, G., de Lara, C., Baban, D., et al. (2015). Adenoviral vector vaccination induces a conserved program of CD8(+) T cell memory differentiation in mouse and man. Cell Reports, 13, 1578\u20131588.","journal-title":"Cell Reports"},{"issue":"13","key":"4181_CR103","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","volume":"385","author":"PT Heath","year":"2021","unstructured":"Heath, P. T., Galiza, E. P., Baxter, D. N., Boffito, M., Browne, D., Burns, F., Chadwick, D. R., Clark, R., Cosgrove, C., Galloway, J., & Goodman, A. L. (2021). Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. New England Journal of Medicine, 385(13), 1172\u20131183. https:\/\/doi.org\/10.1056\/NEJMoa2107659","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"4181_CR104","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41591-020-1124-9","volume":"27","author":"JV Lazarus","year":"2021","unstructured":"Lazarus, J. V., Ratzan, S. C., Palayew, A., Gostin, L. O., Larson, H. J., Rabin, K., Kimball, S., & El-Mohandes, A. (2021). A global survey of potential acceptance of a COVID-19 vaccine. Nature Medicine, 27(2), 225\u2013228.","journal-title":"Nature Medicine"},{"issue":"3","key":"4181_CR105","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.jiph.2020.12.025","volume":"14","author":"M ElBagoury","year":"2021","unstructured":"ElBagoury, M., Tolba, M. M., Nasser, H. A., Jabbar, A., Elagouz, A. M., Aktham, Y., & Hutchinson, A. (2021). The find of COVID-19 vaccine: Challenges and opportunities. Journal of Infection and Public Health, 14(3), 389\u2013416. https:\/\/doi.org\/10.1016\/j.jiph.2020.12.025","journal-title":"Journal of Infection and Public Health"},{"issue":"5","key":"4181_CR106","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","volume":"8","author":"X Yang","year":"2020","unstructured":"Yang, X., Yu, Y., Xu, J., Shu, H., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., Yu, T., & Wang, Y. (2020). Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. The Lancet Respiratory Med, 8(5), 475\u2013481.","journal-title":"The Lancet Respiratory Med"},{"key":"4181_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2020.110335","volume":"145","author":"NK Sharma","year":"2020","unstructured":"Sharma, N. K., Sarode, S. C., Sarode, G., & Patil, S. (2020). Is a COVID-19 vaccine developed by nature already at work? Medical Hypotheses, 145, 110335.","journal-title":"Medical Hypotheses"},{"key":"4181_CR108","doi-asserted-by":"publisher","unstructured":"Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020). Prospects for a safe COVID-19 vaccine. Science Translational Medicine, 12(568), p.eabe0948. https:\/\/doi.org\/10.1126\/scitranslmed.abe0948","DOI":"10.1126\/scitranslmed.abe0948"},{"key":"4181_CR109","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1056\/NEJMp2005630","volume":"382","author":"N Lurie","year":"2020","unstructured":"Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020). Developing Covid-19 vaccines at pandemic speed. New England Journal of Medicine, 382, 1969\u20131973.","journal-title":"New England Journal of Medicine"},{"issue":"6494","key":"4181_CR110","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1126\/science.abc5312","volume":"368","author":"L Corey","year":"2020","unstructured":"Corey, L., Mascola, J. R., Fauci, A. S., & Collins, F. S. (2020). A strategic approach to COVID-19 vaccine R&D. Science, 368(6494), 948\u2013950.","journal-title":"Science"},{"issue":"6518","key":"4181_CR111","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1126\/science.abe5938","volume":"370","author":"M Lipsitch","year":"2020","unstructured":"Lipsitch, M., & Dean, N. E. (2020). Understanding COVID-19 vaccine efficacy. Science, 370(6518), 763\u2013765.","journal-title":"Science"},{"key":"4181_CR112","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.bbi.2021.03.008","volume":"94","author":"E Robertson","year":"2021","unstructured":"Robertson, E., Reeve, K. S., Niedzwiedz, C. L., Moore, J., Blake, M., Green, M., Katikireddi, S. V., & Benzeval, M. J. (2021). Predictors of COVID-19 vaccine hesitancy in the UK household longitudinal study. Brain, Behavior, and Immunity., 94, 41\u201350.","journal-title":"Brain, Behavior, and Immunity."},{"issue":"20","key":"4181_CR113","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1056\/NEJMoa2102214","volume":"384","author":"SA Madhi","year":"2021","unstructured":"Madhi, S. A., Baillie, V., Cutland, C. L., Voysey, M., Koen, A. L., Fairlie, L., Padayachee, S. D., Dheda, K., Barnabas, S. L., Bhorat, Q. E., & Briner, C. (2021). Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B. 1.351 variant. The New England Journal of Medicine., 384(20), 1885\u20131898.","journal-title":"The New England Journal of Medicine."},{"issue":"15","key":"4181_CR114","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","volume":"384","author":"N Dagan","year":"2021","unstructured":"Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hern\u00e1n, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021). BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. New England Journal of Medicine, 384(15), 1412\u20131423.","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"4181_CR115","doi-asserted-by":"publisher","DOI":"10.1111\/xen.12562","volume":"27","author":"H Chung","year":"2020","unstructured":"Chung, H., Kim, H. J., Kim, J. S., Yoon, I. H., Min, B. H., Shin, J. S., Kim, J. M., Lee, W. W., & Park, C. G. (2020). CD4+\/CD8+ T-cell ratio correlates with the graft fate in pig-to-non-human primate islet xenotransplantation. Xenotransplantation, 27(2), e12562.","journal-title":"Xenotransplantation"},{"issue":"10253","key":"4181_CR116","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(20)31821-3","volume":"396","author":"P Krause","year":"2020","unstructured":"Krause, P., Fleming, T. R., Longini, I., Henao-Restrepo, A. M., Peto, R., Dean, N. E., Halloran, M. E., Huang, Y., Fleming, T. R., Gilbert, P. B., & DeGruttola, V. (2020). COVID-19 vaccine trials should seek worthwhile efficacy. The Lancet, 396(10253), 741\u2013743.","journal-title":"The Lancet"},{"issue":"9","key":"4181_CR117","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1016\/j.drudis.2020.06.020","volume":"25","author":"N Theobald","year":"2020","unstructured":"Theobald, N. (2020). Emerging vaccine delivery systems for COVID-19: Functionalised silica nanoparticles offer a potentially safe and effective alternative delivery system for DNA\/RNA vaccines and may be useful in the hunt for a COVID-19 vaccine. Drug Discovery Today, 25(9), 1556.","journal-title":"Drug Discovery Today"},{"issue":"6","key":"4181_CR118","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1080\/21645515.2020.1735227","volume":"16","author":"K Dhama","year":"2020","unstructured":"Dhama, K., Sharun, K., Tiwari, R., Dadar, M., Malik, Y. S., Singh, K. P., & Chaicumpa, W. (2020). COVID-19, an emerging coronavirus infection: Advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Human vaccines & immunotherapeutics, 16(6), 1232\u20131238.","journal-title":"Human vaccines & immunotherapeutics"},{"issue":"7","key":"4181_CR119","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.3390\/biom11071020","volume":"11","author":"K Lundstrom","year":"2021","unstructured":"Lundstrom, K., Barh, D., Uhal, B. D., Takayama, K., Aljabali, A. A., El-Aziz, A., Mohamed, T., Lal, A., Redwan, E. M., Adadi, P., & Chauhan, G. (2021). COVID-19 Vaccines and Thrombosis\u2014Roadblock or Dead-End Street? Biomolecules, 11(7), 1020.","journal-title":"Biomolecules"},{"key":"4181_CR120","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5414\/ALX02215E","volume":"5","author":"J Kleine-Tebbe","year":"2021","unstructured":"Kleine-Tebbe, J., Klimek, L., Hamelmann, E., Pfaar, O., Taube, C., Wagenmann, M., Werfel, T., & Worm, M. (2021). Severe allergic reactions to the COVID-19 vaccine\u2013statement and practical consequences. Allergologie select., 5, 26.","journal-title":"Allergologie select."},{"issue":"4","key":"4181_CR121","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1182\/blood.2021011958","volume":"138","author":"A Tiede","year":"2021","unstructured":"Tiede, A., Sachs, U. J., Czwalinna, A., Werwitzke, S., Bikker, R., Krauss, J. K., Donnerstag, F., Wei\u00dfenborn, K., H\u00f6glinger, G., Maasoumy, B., & Wedemeyer, H. (2021). Prothrombotic immune thrombocytopenia after COVID-19 vaccination. Blood, 138(4), 350\u2013353. https:\/\/doi.org\/10.1182\/blood.2021011958","journal-title":"Blood"},{"key":"4181_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.104865","volume":"29","author":"J Morena","year":"2020","unstructured":"Morena, J., May, C., & Strohm, T. (2020). Acute thrombocytopenia after tissue plasminogen activator for stroke. Journal of Stroke and Cerebrovascular Diseases, 29, 104865.","journal-title":"Journal of Stroke and Cerebrovascular Diseases"},{"key":"4181_CR123","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1089\/hum.2015.154","volume":"27","author":"N Raddi","year":"2016","unstructured":"Raddi, N., Vigant, F., Wagner-Ballon, O., Giraudier, S., Custers, J., Hemmi, S., & Benihoud, K. (2016). Pseudotyping serotype 5 adenovirus with the fiber from other serotypes uncovers a key role of the fiber protein in adenovirus 5-Induced thrombocytopenia. Human Gene Therapy, 27, 193\u2013201.","journal-title":"Human Gene Therapy"},{"key":"4181_CR124","unstructured":"World Health Organization, (2021).\u00a0Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19): interim guidance, 19 July 2021\u00a0(No. WHO\/2019-nCoV\/TTS\/2021.1). World Health Organization."},{"issue":"03","key":"4181_CR125","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1055\/a-1469-7481","volume":"41","author":"J Oldenburg","year":"2021","unstructured":"Oldenburg, J., Klamroth, R., Langer, F., Albisetti, M., Von Auer, C., Ay, C., Korte, W., Scharf, R. E., Potzsch, B., & Greinacher, A. (2021). Diagnosis and management of vaccine-related thrombosis following AstraZeneca COVID-19 vaccination: Guidance statement from the GTH. Hamostaseologie, 41(03), 184\u2013189. https:\/\/doi.org\/10.1055\/a-1469-7481","journal-title":"Hamostaseologie"},{"key":"4181_CR126","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","volume":"384","author":"A Greinacher","year":"2021","unstructured":"Greinacher, A., Thiele, T., Warkentin, T. E., Weisser, K., Kyrle, P. A., & Eichinger, S. (2021). Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. New England Journal of Medicine, 384, 2092\u20132101.","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"4181_CR127","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12529","volume":"5","author":"M Makris","year":"2021","unstructured":"Makris, M., Pavord, S., Lester, W., Scully, M., & Hunt, B. (2021). Vaccine-induced immune thrombocytopenia and thrombosis (VITT). Research and practice in thrombosis and haemostasis, 5(5), e12529.","journal-title":"Research and practice in thrombosis and haemostasis"},{"issue":"8","key":"4181_CR128","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1136\/gutjnl-2020-321388","volume":"69","author":"M Effenberger","year":"2020","unstructured":"Effenberger, M., Grabherr, F., Mayr, L., Schwaerzler, J., Nairz, M., Seifert, M., et al. (2020). Faecal calprotectin indicates intestinal inflammation in COVID-19. Gut, 69(8), 1543\u20131544. https:\/\/doi.org\/10.1136\/gutjnl-2020-321388","journal-title":"Gut"},{"issue":"2","key":"4181_CR129","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M., Kleine-Weber, H., Schroeder, S., Kr\u00fcger, N., Herrler, T., Erichsen, S., et al. (2020). \u2018SARS-Cov-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, 181(2), 271-280.e8. https:\/\/doi.org\/10.1016\/j.cell.2020.02.052","journal-title":"Cell"},{"issue":"577","key":"4181_CR130","doi-asserted-by":"publisher","first-page":"eabd2223","DOI":"10.1126\/scitranslmed.abd2223","volume":"13","author":"D Sterlin","year":"2021","unstructured":"Sterlin, D., Mathian, A., Miyara, M., Mohr, A., Anna, F., Cla\u00ebr, L., et al. (2021). Iga dominates the early neutralizing antibody response to SARS-Cov-2. Sci. Transl. Med., 13(577), eabd2223. https:\/\/doi.org\/10.1126\/scitranslmed.abd2223","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"4181_CR131","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1093\/ibd\/izx029","volume":"24","author":"P Gon\u00e7alves","year":"2018","unstructured":"Gon\u00e7alves, P., Ara\u00fajo, J. R., & Di Santo, J. P. (2018). A cross-talk between microbiota-derived short-chain fatty acids and the host mucosal immune system regulates intestinal homeostasis and inflammatory bowel disease. Inflammatory Bowel Disease, 24(3), 558\u2013572. https:\/\/doi.org\/10.1093\/ibd\/izx029","journal-title":"Inflammatory Bowel Disease"},{"key":"4181_CR132","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejphar.2018.05.003","volume":"831","author":"M Li","year":"2018","unstructured":"Li, M., van Esch, B. C., Wagenaar, G. T., Garssen, J., Folkerts, G., & Henricks, P. A. (2018). Pro- and anti-inflammatory effects of short chain fatty acids on immune and endothelial cells. European Journal of Pharmacology, 831, 52\u201359. https:\/\/doi.org\/10.1016\/j.ejphar.2018.05.003","journal-title":"European Journal of Pharmacology"},{"key":"4181_CR133","doi-asserted-by":"publisher","unstructured":"Gou, W., Fu, Y., Yue, L., Chen, G-d., Cai, X., Shuai, M., et al., (2020). Gut Microbiota may underlie the predisposition of healthy individuals to COVID19. medRxiv 2020.04.22.20076091. doi: https:\/\/doi.org\/10.1101\/2020.04.22.20076091.","DOI":"10.1101\/2020.04.22.20076091."},{"issue":"15","key":"4181_CR134","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1093\/cid\/ciaa709","volume":"71","author":"S Gu","year":"2020","unstructured":"Gu, S., Chen, Y., Wu, Z., Chen, Y., Gao, H., Lv, L., et al. (2020). Alterations of the gut microbiota in patients with COVID-19 or H1N1 influenza. Clinical Infectious Diseases, 71(15), 2669\u20132678. https:\/\/doi.org\/10.1093\/cid\/ciaa709","journal-title":"Clinical Infectious Diseases"},{"key":"4181_CR135","doi-asserted-by":"publisher","unstructured":"Kim, H. S. (2021). Do an altered gut microbiota and an associated leaky gut affect COVID-19 severity? MBio, 12(1), pp.e03022\u201320. https:\/\/doi.org\/10.1128\/mBio.03022-20","DOI":"10.1128\/mBio.03022-20"},{"issue":"20","key":"4181_CR136","doi-asserted-by":"publisher","first-page":"30305","DOI":"10.1016\/j.jhep.2020.05.013","volume":"S0168\u20138278","author":"AM Moon","year":"2020","unstructured":"Moon, A. M., Webb, G. J., Aloman, C., et al. (2020). High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry. Journal of Hepatology, S0168\u20138278(20), 30305\u201330306. https:\/\/doi.org\/10.1016\/j.jhep.2020.05.013","journal-title":"Journal of Hepatology"},{"issue":"20","key":"4181_CR137","doi-asserted-by":"publisher","first-page":"30365","DOI":"10.1016\/j.jhep.2020.06.001","volume":"S0168\u20138278","author":"M Iavarone","year":"2020","unstructured":"Iavarone, M., D\u2019Ambrosio, R., Soria, A., et al. (2020). High rates of 30-day mortality in patients with cirrhosis and COVID-19. Journal of Hepatology, S0168\u20138278(20), 30365\u201330372. https:\/\/doi.org\/10.1016\/j.jhep.2020.06.001","journal-title":"Journal of Hepatology"},{"issue":"3","key":"4181_CR138","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.jmii.2020.03.005","volume":"53","author":"D Wu","year":"2020","unstructured":"Wu, D., & Yang, X. O. (2020). TH17 responses in cytokine storm of COVID19: An emerging target of JAK2 inhibitor fedratinib. Journal of Microbiology, Immunology, and Infection, 53(3), 368\u2013370. https:\/\/doi.org\/10.1016\/j.jmii.2020.03.005","journal-title":"Journal of Microbiology, Immunology, and Infection"},{"issue":"12","key":"4181_CR139","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/j.dld.2020.09.009","volume":"52","author":"V Cardinale","year":"2020","unstructured":"Cardinale, V., Capurso, G., Ianiro, G., Gasbarrini, A., Arcidiacono, P. G., & Alvaro, D. (2020). Intestinal permeability changes with bacterial translocation as key events modulating systemic host immune response to SARS-Cov-2: A working hypothesis. Digestive and Liver Disease, 52(12), 1383\u20131389. https:\/\/doi.org\/10.1016\/j.dld.2020.09.009","journal-title":"Digestive and Liver Disease"},{"issue":"12","key":"4181_CR140","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007390","volume":"14","author":"J Olejnik","year":"2018","unstructured":"Olejnik, J., Hume, A. J., & M\u00fchlberger, E. (2018). Toll-like receptor 4 in acute viral infection: Too much of a good thing. PLoS Pathogens, 14(12), e1007390. https:\/\/doi.org\/10.1371\/journal.ppat.1007390","journal-title":"PLoS Pathogens"},{"issue":"4","key":"4181_CR141","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1002\/jmv.27485","volume":"94","author":"S Falahi","year":"2022","unstructured":"Falahi, S., & Kenarkoohi, A. (2022). Host factors and vaccine efficacy: Implications for COVID-19 vaccines. Journal of Medical Virology, 94(4), 1330\u20131335.","journal-title":"Journal of Medical Virology"},{"issue":"2","key":"4181_CR142","doi-asserted-by":"publisher","first-page":"e362","DOI":"10.1542\/peds.2013-3937","volume":"134","author":"MN Huda","year":"2014","unstructured":"Huda, M. N., Lewis, Z., Kalanetra, K. M., et al. (2014). Stool microbiota and vaccine responses of infants. Pediatrics, 134(2), e362\u2013e372.","journal-title":"Pediatrics"},{"issue":"1","key":"4181_CR143","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41577-021-00554-7","volume":"22","author":"DJ Lynn","year":"2022","unstructured":"Lynn, D. J., Benson, S. C., Lynn, M. A., & Pulendran, B. (2022). Modulation of immune responses to vaccination by the microbiota: implications and potential mechanisms. Nature Reviews Immunology, 22(1), 33\u201346. https:\/\/doi.org\/10.1038\/s41577-021-00554-7","journal-title":"Nature Reviews Immunology"},{"issue":"4","key":"4181_CR144","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3390\/vaccines8040636","volume":"8","author":"R Cianci","year":"2020","unstructured":"Cianci, R., Franza, L., Massaro, M. G., Borriello, R., De Vito, F., & Gambassi, G. (2020). The interplay between immunosenescence and microbiota in the efficacy of vaccines. Vaccines, 8(4), 636.","journal-title":"Vaccines"},{"issue":"1","key":"4181_CR145","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/infdis\/jiw518","volume":"215","author":"VC Harris","year":"2017","unstructured":"Harris, V. C., Armah, G., Fuentes, S., et al. (2017). Significant correlation between the infant gut microbiome and rotavirus vaccine response in rural Ghana. Journal of Infectious Diseases, 215(1), 34\u201341.","journal-title":"Journal of Infectious Diseases"}],"container-title":["Applied Biochemistry and Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12010-022-04181-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12010-022-04181-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12010-022-04181-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T18:40:22Z","timestamp":1684867222000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12010-022-04181-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,12]]},"references-count":145,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["4181"],"URL":"https:\/\/doi.org\/10.1007\/s12010-022-04181-3","relation":{},"ISSN":["0273-2289","1559-0291"],"issn-type":[{"value":"0273-2289","type":"print"},{"value":"1559-0291","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,12]]},"assertion":[{"value":"28 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable<b>.<\/b>","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All authors have approved the manuscript and agree with its submission to Applied Biochemistry and Biotechnology.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}